Introduction
Hyperuricemia, marked by high serum levels of uric acid, is the major etiological cause of gout and the most common inflammatory arthritis in human. 1, 2 Modulation of the overproduction and/or underexcretion of uric acid represents a rational approach
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li et al in the management of hyperuricemia. 3 Morin (3,5,7,2′,4′-pentahydroxyflavone), one of the flavonoids that is extensively present in most medicinal herbs, is well known for its anti-inflammatory, anticancer and antioxidant activities. [4] [5] [6] Previous studies have shown that Morin remarkably inhibited uric acid production and reduced renal urate absorption in vitro, demonstrating its potent antihyperuricemic efficacy. 7, 8 However, translation of the in vitro findings into effective in vivo antihyperuricemic activities remains lacking. In particular, available data on antihyperuricemic activities of Morin through intravenous administration are presently scarce.
The practical use of Morin is limited mainly due to its poor water solubility and short serum half-life (0.37 h), as determined in our present study. This may result in insufficient drug levels in plasma to produce a clinically relevant effect. 9 Our group previously developed a self-nanoemulsifying drug delivery system-loaded Morin phospholipid complex with enhanced water solubility and oral absorption. 9, 10 However, the nanoemulsions failed to extend the serum half-life of Morin, due to extensive first-pass metabolism of Morin after oral administration. Recently, Morin hydrate niosomes have been successfully prepared with improved water solubility and drug entrapment efficiency but also showed minimal effect on the half-life of Morin after intravenous injection. 11 Moreover, the drug loading (DL) efficiency was very low (,4%), causing excessive uses of excipients.
Recognizing these issues associated with the in vivo delivery of Morin, we hypothesized that a systemically administered Morin formulation with both prolonged circulation half-life and high DL capacity would overcome its poor water solubility and best facilitate its use in hyperuricemia treatment. Hydroxyethyl starch (HES), a semi synthetic derivative of starch polysaccharide, is widely used as a colloidal plasma volume expander due to the negligible toxicity and immunity to the body. 12, 13 Compared with native starch, the abundant groups of HES is expected to have longer body circulation time and is more feasible for modification or functionalization.
14 Although HES is considered as a naturally derived substitute for the often used water-soluble PEG, a few HES-based nanoplatforms have been reported. Previously, HES has been hydrophobically modified with stearic acid. 12 However, HES-stearic acid conjugates show poorly self-assembled properties and wide size distribution, which is undesirable for drug delivery. Therefore, the strategy to fabricate stable HES-based nanoparticles (NPs) for efficient drug delivery remains an alluring but great challenge.
We here report a novel HES-based amphiphilic polymer loaded with flavonoid Morin for in vivo treatment of hyperuricemia in a rat model. Deoxycholic acid (DOCA), a natural compound with well-known amphiphilicity to form micelles in water, was selected as the hydrophobic segment of the polymer. It was expected that the introduction of DOCA into HES would induce better self-assembled performance of NPs than stearic acid. Our results demonstrated that the systemically delivered HES-based nanoformulation significantly improved DL, prolonged in vivo circulation time of Morin and thus enhanced therapeutic efficacy for treating hyperuricemia.
Materials and methods Materials
HES (130/0.4) was purchased from Nanjing Duly Biotech Co., Ltd. N,N-dicyclohexylcarbodiimide (DCC), Nhydroxysuccinimide (NHS) and DOCA were purchased from Aladdin Reagent Inc. (Shanghai, People's Republic of China). Pyrene was purchased from Sigma-Aldrich. The other reagents were of analytical grade and used without further purification.
Male Wistar rats were provided by the Laboratory Animal Center of Zhengzhou University (Zhengzhou, People's Republic of China). All animal experiments were approved by the Institutional Animal Care and Ethic Committee of Zhengzhou University, according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals Chinese Version" (2006) . The rats were allowed to acclimate for at least 1 week and fasted overnight with free access to water prior to experiments.
synthesis of hes-DOca conjugates
Amphiphilic HES-DOCA conjugates were prepared by chemical grafting DOCA to HES through ester formation. Briefly, the carboxyl groups of DOCA were reactivated by DCC (1.5 eq.) and NHS (1.5 eq.) in anhydrous tetrahydrofuran at room temperature for 24 h. The formed precipitate (dicyclohexylurea) was removed by filtration. Excess amount of n-hexane was added to the light yellow filtrate under constant stirring. After filtration, the residue was washed with n-hexane and dried under vacuum overnight to obtain NHS ester of DOCA (DOCA-NHSE). In total, 250 mg of HES (0.6 mmoL) was dried at 80°C under vacuum overnight before dissolving in 10 mL of redistilled N,N-dimethylformamide in a round bottomed flask. To the solution were added different amounts of DOCA-NHSE and N,N-diisopropylethylamine, 
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Self-assembled HES nanoparticles-loaded Morin for hyperuricemia therapy in which the molar ratio of DOCA-NHSE to HES varied from 0.2 to 2. The flask was tightly sealed and stirred for 24 h at 40°C. Then, the reactant mixture was dialyzed against excess amount of distilled water/ethanol (1:2, v/v) for 3 days and distilled water for 1 day using a dialysis bag (molecular cutoff 20 kDa), respectively. After being freeze-dried, HES-DOCA conjugate was obtained as a white powder.
characterization of hes-DOca conjugates
The chemical structure of HES-DOCA conjugates was confirmed using 1 H-NMR (Bruker Avance III 400) and FTIR spectrometer (Nicolet iS10 spectrometer, Thermo Fisher Scientific, Waltham, MA, USA 
Determination of the substitution degree of hes by DOca
The amount of DOCA covalently bounded to HES was determined spectrophotometrically as previously described. 15 Briefly, the polymer sample (5-10 mg) was accurately weighed and dissolved in 0.5 mL DMSO. Then, 0.5 mL acetic acid solution (60%) and 9.0 mL water/sulfuric acid (65/50, v/v) were subsequently added. The samples were vortexed to homogeneity, heated at 70°C for 30 min and then cooled to room temperature. The UV (Lambda 35, PerkinElmer Inc., Waltham, MA, USA) absorbance of sample solution was read at 380 nm. Meanwhile, the sample containing the same components without the polymer was used as blank control. Standard calibration curves of DOCA concentration under the abovementioned condition were established. The degree of substitution (DS, mol%, expressed as mole DOCA/100 sugar residues of HES) was calculated according to the following formula:
where m DOCA is the mass ratio of DOCA in HES-DOCA conjugates calculated from the established calibration curve; M DOCA is the molecular weight of the DOCA residue, m HES-DOCA is the amount of the HES-DOCA conjugates, M HES is the average molecular weight of glucose units of HES.
Preparation of self-assembled hes-DOca NPs
To prepare the self-assembled HES-DOCA NPs, 20 mg of HES-DOCA conjugates were dispersed into 2 mL of acetone and the dispersions were further added dropwise in 4 mL of phosphate-buffered saline (PBS, pH 7.4). The mixture was sonicated at 100 w (Automatic Ultrasonic Processor UH-500A, People's Republic of China) in an ice bath for 10 min followed by stirring at room temperature overnight to remove organic solvents. The resultant mixture was passed through 0.45 μm filter membrane to obtain self-assembled HES-DOCA NPs. To prepare the self-assembled HES-DOCA nanoparticles-loaded Morin (Morin/HES-DOCA-NPs), 20 mg of amphiphilic HES-DOCA conjugates and 4 mg Morin were dispersed into 2 mL of acetone. Then, the dispersion was processed as described previously to obtain Morin/ HES-DOCA-NPs.
characterization of self-assembled hes-DOca NPs
The average particle size and size distribution of the selfassembled NPs were measured in triplicate by photon correlation spectroscopy (Zetasizer Nano ZS90, Malvern Instruments, Malvern, UK). The morphology of NP-loaded Morin was observed by a transmission electron microscopy (TEM) instrument (H-600, Hitachi Ltd., Tokyo, Japan). The TEM specimens were prepared by depositing the NPs suspension onto a copper grid followed by negatively staining with 1% phosphotungstic acid for 10 s. Morin concentrations both in vitro and in vivo samples were analyzed on a Waters ® 2690 HPLC system equipped with a Waters 996 Photodiode Array Detector (Waters, Milford, MA, USA) as we reported previously. 16 A Zorbax SB-C 18 analytical column (Agilent, 150 × 4.6 mm 2 , 5 μm) was used with a mobile phase consisting of acetonitrile and 0.5% phosphoric acid (24:76, v/v) with a flow rate of 1.0 mL/min. The detection wavelength was 252 nm. The DL and encapsulation efficiency (EE) were calculated by the following equations:
DL%
Weight of the drug in nanoparticles Weight of the feedi = n ng polymer and drug 100% ×
EE%
Weight of the drug in nanoparticles Weight of the feedi = n ng drug 100% ×
In vitro release of Morin/HES-DOCA-NPs
In vitro release studies were performed using a dialysis method in phosphate buffer solutions (pH 7.4) at 37°C. The dialysis bags (MWCO of 3500) were first soaked in medium for 12 h before use. In total, 1 mL of freshly prepared Morin solution or Morin/HES-DOCA-NPs (diluted with release medium, 0.5 mg/mL) was added to the bags, which were placed in antibiotic bottles containing 50 mL of the release medium and shaken at 100 rpm. At designated time points, 1 mL of the release medium was withdrawn, and replaced by an equal volume of fresh media. The samples collected were analyzed using HPLC as described previously.
In vivo pharmacokinetic studies
Rats were randomly divided into two groups (n = 5) and fasted overnight before administration. One group was given intravenously Morin saline solution at 2 mg/kg. The other group was given Morin/HES-DOCA-NPs at an equivalent dose of 2 mg/kg. Blood (400 μL) was collected via orbital sinus puncture into heparinized tubes at designated time points post injection. Plasma was separated from whole blood by centrifugation (1,296 × g, 5 min). The sample procession was adopted from previous work. 10 Briefly, rat plasma (100 μL) was mixed with 100 μL 25% hydrochloric acid and 200 μL of methanol containing 30 μg/mL benzoic acid as internal standard. The mixture was further incubated in 50°C water bath for 0.5 h. After centrifugation (12,544 × g, 15 min), the supernatant (100 μL) was injected directly into the HPLC column.
The pharmacokinetic parameters, such as the area under the plasma concentration-time curve (AUC), elimination half-life and mean residence time were determined by DAS 3.0 software (Mathematical Pharmacology Professional Committee of China).
animal model of hyperuricemic rats and drug administration
A hyperuricemia model in rats was established using uricase inhibitor potassium oxonate as we described previously. 9 Rats were randomly assigned to four groups (n = 10) as follows: normal group; hyperuricemic control group; Morin-treated group and Morin/HES-DOCA-NPs-treated group. Prior to experimental procedure, blank serum of all these four groups was collected via orbital puncture. Then potassium oxonate suspension in 0.5% CMC-Na was intraperitoneally injected to rats at the dose of 250 mg/kg, while normal saline of similar volume was injected into each rat of the normal group. Blood samples were collected from each rat 1 h postinjection. Thereafter, the induced hyperuricemic rats were intravenously given Morin solutions and Morin/HES-DOCA-NPs at an equivalent dose of 2 mg/kg Morin, respectively. The normal and hyperuricemic control group (non-treated) were intravenously given a similar volume of normal saline. For each group, 0.5 mL of plasma was collected via orbital puncture at designated time points and centrifuged at 10,000 × g for 5 min to obtain serum. The serum uric acid, creatine and urea nitrogen levels of the samples were determined by an automatic biochemical analyzer using the corresponding kit (Hitachi 7020). In the end, kidneys were separated from sacrificed rats and fixed in 4% buffered formalin. Each was then paraffin embedded and sectioned for hematoxylin and eosin staining for conventional histological examination. Photomicrographs were taken with a microscope camera at 200× magnification.
Determination of uric acid excretion, hepatic and serum xanthine dehydrogenase/xanthine oxidase (XDH/XO) activity in hyperuricemic rats
Rats were housed individually in metabolic cages and allowed free access to water during the period of the experiment. After the abovementioned procedures, urine was collected for 5 h after each drug treatment. Thereafter, blood samples of the animals were collected by orbital puncture. The uric acid and creatinine levels in serum of the animals were determined using the automatic biochemical analyzer. After being killed by decapitation, the liver tissues of rats were dissected rapidly and were homogenized in 10 volumes of ice-cold saline. After centrifugation (6,000 × g, 10 min), the XDH/XO activity of the supernatant was determined using a spectrophotometric method by XDH/XO assay kits (Nanjing Jiancheng Co., People's Republic of China). XDH/XO activity was expressed as per μmoL xanthine yielded per g per minute of tissue protein.
Urine uric acid concentration was analyzed by HPLC as described in our earlier studies. 9 Urine creatine levels were determined by the automatic biochemical analyzer. Figure 1A) , the characteristic peaks of HES located between 4.5 and 5.6 ppm, which could be assigned to the hydroxyl groups from glucose unit of HES. 17, 18 Successful introduction of DOCA into HES polymers was validated by the peaks of DOCA appearing at 0.6-2.5 ppm. 19 The formation of ester linkage between DOCA and HES was also evidenced in the FTIR spectra ( Figure 1B) . The characteristic peak of DOCA at 2,936 and 2,862 cm −1 [ Figure 1B (a)] was assigned to the stretching vibration of DOCA. 15 A significant shift at 1,687 cm Table 1 . The mean size of self-assembled NPs of HES-DOCA conjugates with different DS was in the range of 159 and 235 nm in PBS solution (pH 7.4) as determined by dynamic light scattering (DLS). The polydispersity index was less than 0.2 for all the prepared HES-DOCA NPs, indicated that the HES-DOCA NPs formed in PBS solution were monodispersed with narrow particle size distribution. Zeta potential indicated that HES-DOCA NPs were covered with negatively charged HES shells from −7 to −18.9 mV, leading to a repelling force between particles with increased stability. Considering the optimal size of NPs for drug delivery, the DS value was controlled around 10% for HES-DOCA conjugates in the following formulation studies. Using the pyrene-based fluorescence technique, the critical aggregation concentration of HES-DOCA conjugates with DS of 10% was determined as 0.0215 mg/mL.
Scheme 1
The synthesis scheme of hes-DOca conjugates (A) and schematic illustration of DOCA-mediated self-assembled HES-based nanoparticles (B). Abbreviations: hes, hydroxyethyl starch; DOca, deoxycholic acid; hes-DOca, hydroxyethyl starch-deoxycholic acid. Morin was easily encapsulated into HES-DOCA NPs using a simple combination of solvent evaporation and sonication approaches. The brush-like structured core of NPs was self-aggregated by hydrophobic effects of DOCA, while the hydrophilic HES backbone comprised the shell of NPs, as shown in Scheme 1B. DLS measurement demonstrated that the mean particle size of Morin/HES-DOCA-NPs was 197 nm with a polydispersity index value of 0.05 and a zeta potential of −14 mV (Figure 2A ). TEM results showed that self-assembled HES NPs were spherical, and their sizes were smaller than the results determined by DLS measurement ( Figure 2B ). The DL was 92.5% and the EE was 15.6%. 
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The in vitro release profile of Morin from HES-DOCA conjugates in PBS solution (pH 7.4) is shown in Figure 2C . Free Morin released quickly in PBS solution, which was also demonstrated in our previous study, probably due to the better solubility of free Morin at higher pH values. 16 By contrast, Morin was gradually released from HES-DOCA NPs over an extended period. No obvious burst release effects were observed in Morin/HES-DOCA-NPs, indicating Morin was loaded mainly in the hydrophobic core of HES-DOCA NPs but was not physically adsorbed onto its hydrophilic outer shell.
Pharmacokinetic of Morin/HES-DOCANPs after intravenous administration
The mean plasma concentration-time curves of Morin and Morin/HES-DOCA-NPs via tail vein injection are shown in Figure 3 . Compared with Morin, Morin/HES-DOCA-NPs exhibited remarkably higher plasma level and extended clearance time from the plasma after injection in rats. Specifically, the plasma concentrations of Morin were significantly higher in rats administered with Morin/HES-DOCA-NPs than those administered with Morin solution at all time points postinjection. In addition, free Morin was rapidly eliminated from plasma and hardly detected 5 h after administration of Morin solution. By contrast, Morin/HES-DOCA-NPs demonstrated significantly longer blood-circulation time than free Morin as Morin was still detectable 12 h postinjection. The relevant pharmacokinetic parameters were obtained using a two compartmental analysis ( Table 2 ). AUC 0-t values were increased to 2.6 times in Morin/HES-DOCA-NPs formulations, compared to free Morin. Remarkably, the half-life of Morin (0.37 h) was significantly enhanced by more than fourfold by the incorporation of Morin into HES-DOCA NPs (1.52 h). These encouraging results suggest a possible higher therapeutic effect of Morin/HES-DOCA-NPs compared with Morin solution.
Reduced serum uric acid level by Morin/ hes-DOca-NPs in hyperuricemic rats
Hyperuricemia group, Morin-treated group and Morin/ HES-DOCA-NPs-treated group demonstrated a significant increase in the serum uric acid level of rats at 2 h, in comparison with blank group (Figure 4A ). Both Morin and Morin/HES-DOCA-NPs treatment reduced the serum uric acid level at 4 h, compared to hyperuricemia group (control), but only Morin/HES-DOCA-NPs further reduced serum uric acid level to normal (55 μmol/L) at 6 h, indicating its superior antihyperuricemic efficacy ( Figure 4B ). Although it is not statistically significant, obvious trends in increasing the serum creatine and nitrogen levels were present between hyperuricemia group and blank group ( Figure 4C and D) , suggesting possible renal injury caused by potassium oxonate. 20, 21 Compared to hyperuricemia rats, Morin/HES-DOCA-NPs treatment demonstrated a marked decrease in the serum creatine and nitrogen levels, which was not observed for Morin treatment. The results suggested that Morin/HES-DOCA-NPs might have protective effects against kidney damage in hyperuricemia rats. As shown in Figure 4E , hyperuricemia group (control) demonstrated significant morphological changes in renal tissue typically characterized by inflammatory cell infiltration, compared with normal rats. Morin-treated groups showed alleviated inflammatory cell influx in the tubule and collecting duct of rats, suggesting that Morin could slightly attenuate rat kidney damage. By contrast, renal tissue in Morin/HES-DOCA-NPs-treated rats preserved normal kidney structure, with minimal morphological changes. Therefore, Morin/HES-DOCA-NPs had superior ability in protecting rat kidney from acute injury than Morin.
Uricosuric effects and inhibitory effect of Morin/HES-DOCA-NPs on hepatic XDH/XO activity in hyperuricemic rats
Both serum and hepatic XDH/XO activity of rats in these four groups were determined to evaluate the inhibitory effect of drugs on production of uric acid in vivo. As shown in Figure 5 , no significant difference was observed among the serum XDH/XO activities of these four groups ( Figure 5A ). Figure 5B demonstrates that Morin/HES-DOCA-NPs significantly decreased XDH/XO activity in liver in comparison with Morin, suggesting the vital role of hepatic XDH/XO activity in modulating uric acid level by Morin/HES-DOCA-NPs. The urine uric acid level was significantly increased by 3.6-fold in the hyperuricemia control rat (without drug treatment) compared with normal rats (Figure S1 ), further confirming that the hyperuricemic rat kidney was injured soon after uric acid level increased. Compared with Morin, Morin/ HES-DOCA-NPs significantly increased urine uric acid level of rats, suggesting the superior uricosuric action of Morin/ HES-DOCA-NPs. Moreover, UA excretion was expressed as fractional excretion (FE UA ). All the other parameters, including urine and plasma creatine levels and urine volume (Figure S1A-C), were measured for the four groups of rats to calculate FE UA . Both Morin and Morin/HES-DOCANPs-treated rats demonstrated significantly higher FE UA values than the normal group ( Figure 5C ). The FE UA value of Morin/HES-DOCA-NPs (0.64) was four times that of Morin (0.16), which further confirmed that Morin/HES-DOCA-NPs significantly improved the uricosuric actions of Morin, contributing to the improved antihyperuricemic effect in rats. 
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Discussion
With an ever-growing aging population and greatly improved living conditions, hyperuricemia has placed a significant burden on the public healthcare system. 22 Morin is one of the medicinally important flavonoids and exhibits not only inhibitory activity against xanthine oxidase but also potent inhibitory action on urate uptake in rat renal brush-border membrane vesicles, indicating its great potential in regulating uric acid level in vivo. 7 Its poor water solubility and short plasma half-life, however, have prevented its clinical use in the treatment of hyperuricemia. 9, 10 To overcome these limitations, we designed an amphiphilic HES-based polymer by conjugating DOCA covalently to the hydroxyl ethyl group of HES. In addition to induce stable HES-based self-assembled NPs, DOCA was also expected to serve as a microcontainer for high DL of poor water-soluble Morin, due to its distinctive amphiphilicity. 19 The outer shell comprising HES with free hydroxyl ethyl groups was expected to display stealth properties in systemic circulation to prolong the half-life of encapsulated Morin and further improve its therapeutic efficacy.
More importantly, from clinical translational perspective, the HES-based amphiphilic polymer design and its NP formulation have significant advantages. HES is currently intensely investigated as a substitute for PEGs. 17 Compared with synthetic PEGs, naturally derived HES shows negligible toxicity and immunity to the body, which opens a new door for exploring in vivo application of naturally derived materials with stealth properties. 23 However, very few studies have reported the design, synthesis and in vivo evaluation of HES-based amphiphilic polymer. 12 Our study is the first to explore the long circulation properties of HES-based nanoplatforms and validate its utility in drug delivery for flavonoid Morin as well as clinically relevant hyperuricemia model.
In this study, we have successfully synthesized HES-DOCA conjugates with different DS of DOCA and the structure was confirmed by analysis of FTIR and 1 H-NMR. As expected, the DS increased as the feed ratio of DOCA-NHSE to the hydroxyethyl sugar residues of HES polymer increased. Interestingly, the mean sizes of self-assembled NPs decreased from 231 to 159 nm when DS of HES-DOCA conjugates increased from 1.2% to 10%, and then 
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Self-assembled HES nanoparticles-loaded Morin for hyperuricemia therapy the mean sizes increased to 235 nm when DS increased to 35%. Based on our preliminary study, water-soluble HES has a mean diameter of about 230 nm in water, probably due to its dendrimer-like properties. Compared with native HES, the size of self-assembled HES-DOCA NPs (DS, 1.2%-10%) slightly decreased mainly due to the hydrophobic force-mediated compaction of HES by DOCA. When DS increased over 10%, the sizes of self-assembled HES-DOCA NPs began to increase probably because of high density of DOCA conjugation-induced larger hydrophobic inner core. Considering both optimal size and suitable DS of DOCA for drug delivery, the HES-DOCA conjugate with a DS of 10% was selected for the following studies. The selected HES-DOCA conjugates have a mean size of 159 nm when selfassembled into NPs and its CMC value was determined to be 0.0215 mg/mL, suggesting that the NPs are stable and may have the capacity to retain their aggregation in the systemic circulation. When formulated with free drug Morin, the mean size of HES-DOCA NPs (DS 10%) increased to 197 nm and exhibited a zeta potential of −14 mV. The size measured by DLS was slightly larger than the results determined by TEM. It was mainly due to the solvent effect of different state of samples. DLS showed the size for the particles swollen in the solution, while TEM images showed the size at the dried state of the samples. 15 In vitro release study showed sustained release of Morin from HES-DOCA NPs for 24 h, confirming the stable encapsulation and ability of NPs to extend the availability of Morin in blood circulation. In vivo pharmacokinetics data support the long circulation of Morin in blood as the half-life of Morin increased by threefold after Morin/HES-DOCA-NPs administration, compared with Morin solution.
The improved therapeutic index of Morin/HES-DOCANPs was validated in an oxonate potassium-induced hyperuricemic rat model. Morin/HES-DOCA-NPs significantly reduced the high serum uric acid level of hyperuricemic rat (145 μmol/L) to normal (55 μmol/L) 5 h post-administration ( Figure 4A ). By contrast, the antihyperuricemic effect of Morin diminished after Morin solution was given intravenously for 5 h, probably due to the short half-life of free Morin in vivo.
The histological examination revealed that the kidney of hyperuricemic rats was injured soon after uric acid level increased, in consistent with previous reports. 24 Morin was previously reported to possess anti-inflammatory effect but showed minimal protective effect against renal inflammation in hyperuricemic rats. 6 It may be due to the insufficient serum level of Morin at the dose of 2 mg/kg for satisfied therapeutic efficacy. In a previous study, we explored the therapeutic mechanism of Morin in vivo and found that Morin inhibited XOD/XDH activity in liver but not in serum. 9 In line with these observations, we found that hepatic XOD/XDH activity played a key role in modulating uric acid level after Morin/ HES-DOCA-NPs treatment in the present study. In addition, Morin/HES-DOCA-NPs greatly improved uric acid excretion from the kidney, as evidenced by the increased FE UA value of NPs-treated rats. Our findings with the systemic delivery of Morin/HES-DOCA-NPs encouraged the continued development of HES-based polymers as a viable nanoplatform to prevent or treat additional diseases.
While the in vivo treatment study validates the therapeutic benefit of Morin/HES-DOCA-NPs, additional studies are necessary to further optimize this new formulation for clinical translation. Our future work will define the potential preferential size and surface properties of HES-based NP formulations during in vivo circulation. The therapeutic efficacy observed in this study was demonstrated in a short-term hyperuricemia rat model. Further studies need to be done in animals with longer term hyperuricemia.
Conclusion
In this study, we report the successful synthesis of a novel amphiphilic polymer based on HES, which could spontaneously self-assemble into stable NPs. The HES-based NPs selfassembled from optimized HES-DOCA conjugates enabled a high DL capacity of Morin. The systemic application of Morin/HES-DOCA-NPs remarkably extended the half-life of Morin and led to superior serum urate lowering effect in vivo. The success of this formulation provided a solid proof for the explorations of HES-based polymers as a viable strategy to extend the in vivo half-life of short-time bioactive drugs. Thus, we believe that the novel self-assembled HES NPs can be applied to additional therapeutic agents to improve the treatment of many other diseases.
